Could an MS Walking Drug Help Vision After Eye Attacks?
By MS Buddy ·
Summarized from Annals of clinical and translational neurology, Oct 2026 · PubMed · DOI. AI-generated summary. Not medical advice.
Research by Hongxuan Wang, Ying Peng and 8 colleagues at Sun Yat-sen University and Shenshan Medical Center of Sun Yat-sen Memorial Hospital in China.
Key Takeaway
In a study of a condition different from MS, people who added fampridine to treatment for a severe eye attack had better vision recovery than those who did not.
What They Found
The study followed people with NMOSD, a condition different from MS that can cause sudden, severe vision loss when the nerve from the eye becomes inflamed. All participants had received high-dose steroids, but their eye attacks had not responded well. Some also took fampridine for three months, while others did not. At three and six months, the fampridine group showed greater improvement on measures of how well they could see and how much their symptoms affected them. At three months, 36% of the fampridine group reached the study’s better-vision score, compared with 7% of the other group.
Who Should Care and Why
People with MS may know fampridine as a medicine used to help some people walk, but this study looked at vision in NMOSD, not MS. That difference matters: a treatment that helps one condition may not help the other. People with NMOSD who have had a severe eye attack may find the results worth discussing with their specialist. Caregivers may find it useful to track changes in everyday tasks, such as reading signs or moving around safely, and share them at appointments. No one should start or change fampridine based on this study alone; a clinician can explain whether it is appropriate for their situation.
Important Considerations
The abstract does not say that people were randomly assigned to treatment, so differences between the groups could have affected the results. It does not report how many people took part or describe side effects, making it hard to judge how reliable or safe the approach was. Because the study involved NMOSD rather than MS, it cannot show that fampridine improves vision after an MS-related eye attack.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Annals of clinical and translational neurology by et al.. Reproduced from the PubMed record.
Neuromyelitis optica spectrum disorders (NMOSD) usually occur with acute refractory optic neuritis (ON). However, there is a lack of efficacious treatments to improve recovery. Since fampridine has been found to improve the prognosis of multiple sclerosis (MS) and MS-related ON, it is necessary to explore the efficacy of fampridine on visual functions in NMOSD-ON. Patients aged 14-80 who suffered from acute refractory AQP4-IgG positive ON within 2 weeks onset and with high-dose corticosteroid treatment were included. Patients treated with sustained-release fampridine (4-aminopyridine, 4-AP) as add-on treatment for 3 months were compared with patients without 4-AP (non-4-AP). Visual functional scores (VFS), Opticospinal Impairment Scale (OSIS), the logarithm of the minimum angle of resolution (LogMAR) of visual acuity (VA), the mean deviation (MD) value of the static visual field, and retina nerve fiber layer (RNFL) thickness were measured and followed up from baseline to 6 months. Patients with 4-AP add-on treatment improved VFS or OSIS greater than that with control (non-4-AP) at 3 and 6 months compared with baseline (all p < 0.05). 4-AP add-on treatment also increased the proportion of better improvement of ON (VFS ≤ 2) at 3 months (36.4% vs. 7.1% in control, p < 0.05 adjusted for plasma exchange), and 4-AP improved visual field at 6 months (p < 0.05 adjusted for plasma exchange). Fampridine as an add-on treatment has potential functional benefit on refractory NMOSD-ON and improves visual functions after the attack of ON.
Trials you could look into
This study looked at a treatment with MS trials currently recruiting or under way.
Listing a trial is not a recommendation. Eligibility is decided by the study team, and your neurologist is the person to ask first.
Explore more research
Check out the MS Buddy app
It’s free, with no ads. Built by people living with MS.
Related MS research
11/8/2026
A study finds a short survey may help spot worry about the unknown in people with MS. Learn what it
Read More
11/7/2026
A study of 360 people with MS links past suicide attempts with depression, smoking, and childhood ha
Read More
11/4/2026
A four-year MS study links the condition of nerve coating in brain lesions with later thinking speed
Read More
11/3/2026
A study of two MS medicines found MRI scans may help confirm relapses and clarify treatment differen
Read More
11/3/2026
A large MS records study found fewer Alzheimer’s diagnoses among people given natalizumab. Learn wha
Read More
11/3/2026
Sexual health concerns are common with MS. Learn how symptoms and pregnancy plans may affect intimac
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.